Merging with a former rival will bolster its capabilities.
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END
The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger.
As AI continues to reshape the drug development landscape, here are three promising small-cap biotech stocks worth considering now.
Exscientia has the potential to be a star collaborator and a profitable drug developer, too.
AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.
The high cost of developing drugs makes the use of artificial intelligence a natural fit for pharmaceutical companies.
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.
Investors continue to look for stocks to buy as inflation cools. As you prepare for another busy week, here are some of our top stories from this week